Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418446

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Eyesight: Testing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many people were diagnosed with (a) a brain tumour and (b) other conditions as a result of symptoms noticed during examinations by opticians in the last 12 months.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10017
answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>Information provided by the Health and Social Care Information Centre shows that during 2013/14 there were 159,626 referrals from optometrists to secondary care. It is not possible, however, to identify a diagnosis given the collection of this information is not mandatory.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 17/09/2015 10:07:37 answering member 1201 label Biography information for Alistair Burt
tabling member	4131 label Biography information for Jim Shannon

418447

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Statins
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure patients prescribed statins can make a choice on what type of statins they receive.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10020
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Decisions regarding the appropriateness of a particular treatment, including statins, should be made by clinicians in partnership with patients. The individual circumstances of each patient should be taken into account, alongside their medical history, needs and preferences.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/09/2015 10:04:02 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

418448

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Smoking
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what information his Department holds on how many people of what age ranges gave up smoking in each of the last five years.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10021
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>The Health and Social Care Information Centre collects this information on behalf of the Department and it is made publicly available at the following web addresses:</p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB00417/nhs-stop-smok-serv-eng-2010-2011-tab.xls" target="_blank">http://www.hscic.gov.uk/catalogue/PUB00417/nhs-stop-smok-serv-eng-2010-2011-tab.xls</a></p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB07011/stat-stop-smok-eng-apr-11-mar-12-tab1.xls" target="_blank">http://www.hscic.gov.uk/catalogue/PUB07011/stat-stop-smok-eng-apr-11-mar-12-tab1.xls</a></p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB12228/stat-stop-smok-serv-eng-apr-12-mar-13-tab1.xls" target="_blank">http://www.hscic.gov.uk/catalogue/PUB12228/stat-stop-smok-serv-eng-apr-12-mar-13-tab1.xls</a></p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB14610/stat-stop-smok-serv-eng-apr-13-mar-14-tab.xlsx" target="_blank">http://www.hscic.gov.uk/catalogue/PUB14610/stat-stop-smok-serv-eng-apr-13-mar-14-tab.xlsx</a></p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/catalogue/PUB18002/stat-stop-smok-serv-eng-annual-1415.xlsx" target="_blank">http://www.hscic.gov.uk/catalogue/PUB18002/stat-stop-smok-serv-eng-annual-1415.xlsx</a></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/09/2015 10:05:51 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

418449

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Alzheimer's Disease: Dental Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will commission a study to investigate potential links between dental treatment and Alzheimer's disease.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10023
answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>The Department has no plans to commission a study on the specific risk of transmission of Alzheimer’s disease in dentistry. There is no evidence that Alzheimer's disease can be transmitted through any medical procedure. In dentistry, patients are protected from the risk of infection by either mandatory single use instruments, or where instruments are reused, by guidance on strict decontamination procedures as per the Health Technical Memorandum 01-05: Decontamination in primary care dental practices - 2013 edition.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 17/09/2015 16:09:59 answering member 1201 label Biography information for Alistair Burt
tabling member	4131 label Biography information for Jim Shannon

418450

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what criteria NICE has set for new dementia treatments to be recommended for provision by the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10022
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The National Institute for Health and Care Excellence assesses significant new drugs and treatments, including those for the treatment of dementia, through its technology appraisal programme. Technology appraisals are conducted in accordance with NICE’s <em>Guide to the methods of technology appraisal 2013</em> which is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/Foreword" target="_blank">www.nice.org.uk/article/pmg9/chapter/Foreword</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:15:57 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

418451

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his policies of the decision by NHS England announced on 4 September 2015 to remove (a) the pancreatic cancer drug Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10091
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>No such assessment has been made. We remain committed to continuing to invest in the Cancer Drugs Fund which has so far benefitted over 72,000 people with cancer in England.</p><p> </p><p> </p><p> </p><p>We understand that NHS England continues to work with manufacturers seeking to maintain drug and indication combinations within the Fund.</p><p> </p><p><strong> </strong></p><p> </p><p>NHS England has confirmed that patients who are already receiving a drug/indication which is to be removed from the Fund will continue to be treated with that drug until they and their clinicians consider it appropriate to discontinue treatment. In addition, drugs removed from the Fund will continue to be available via Individual Funding Requests if the individual patient meets clinical exceptionality criteria.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:22:40 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418452

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what mechanisms there are for appeal against NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10092
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England has advised that the mechanisms for appeal are as set out in Appendix G, section 11 of the Cancer Drugs Fund Standard Operating Procedures which are published on NHS England’s website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:23:43 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418453

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect on cancer clinical trials of NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10093
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>Neither the Department nor NHS England has made any such assessment.</p><p> </p><p> </p><p> </p><p>Advances in medical science means that new cancer medicines are emerging all the time and NHS England needs to regularly prioritise its national Cancer Drugs Fund (CDF) list so people can access these too. Decisions on which treatments are included on the list are made by the CDF expert clinical panel because it is right these decisions are clinically led.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:25:30 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418454

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ehlers-Danlos Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent discussions his Department has had with health bodies on ensuring timely treatment for sufferers of Ehlers-Danlos syndrome.
tabling member constituency	Bury North
tabling member printed	Mr David Nuttall
uin	9988
answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9989 question first answered 21/09/2015 10:00:16 answering member 4020 label Biography information for George Freeman
tabling member	4140 label Biography information for Mr David Nuttall

418455

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the final results of the National Institute for Health Research's ProtecT trials for prostate cancer testing to be published; and if he will make a statement.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	9996
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The ProtecT randomised controlled trial is evaluating the effectiveness, cost-effectiveness and acceptability of active monitoring, radical 3D conformal radiotherapy and radical prostatectomy in men with clinically localised prostate cancer, identified through population-based PSA (Prostate Specific Antigen) testing.</p><p> </p><p> </p><p> </p><p>There have already been over 100 published outputs from ProtecT and these are listed on the National Institute for Health Research (NIHR) website:</p><p> </p><p> </p><p> </p><p>www.nets.nihr.ac.uk/projects/hta/962099</p><p> </p><p> </p><p> </p><p>The researchers plan to publish the primary and most secondary analyses during 2016 at major relevant conferences and in peer-reviewed journals. The primary outcome to be evaluated is definite or probable prostate cancer specific mortality at a median of 10 years following randomisation. A monograph covering these findings is expected to be published in the NIHR Journals Library in July 2017. Findings from longer term follow-up will be published at a later stage.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:17:51 answering member 4020 label Biography information for George Freeman
tabling member	1409 label Biography information for Mr Gregory Campbell